-
Mashup Score: 0Is Surgery a Good Option for Patients With PIK3CA-Related Overgrowth Syndrome (PROS)? - 1 year(s) ago
Dr Guillaume Canaud explains why surgery is usually not an effective treatment in the long-term for patients with PROS.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0EHR-Integrated Patient-Reported Outcomes in Ambulatory Oncology: A Critical Opportunity for Timely and Targeted Palliative Care - 1 year(s) ago
“EHR-Integrated Patient-Reported Outcomes in Ambulatory Oncology: A Critical Opportunity for Timely and Targeted Palliative Care” published on Jan 2023 by National Comprehensive Cancer Network.
Source: JNCCNCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
EHR-Integrated #PROs in Ambulatory Oncology: A Critical Opportunity for Timely & Targeted #PalliativeCare: https://t.co/pHy9a4ZHpO By @drpattymoreno @DrFrankJPenedo @FeliciaKnaul @carina_oltmann @mhubermd @DrMKhawand @sylvestercancer @umiamimedicine #PallOnc https://t.co/F8ccqj5m4f
-
-
Mashup Score: 0
Background: Patient-reported outcomes (PROs) are important measures of treatment effect and can be used to inform the approval of cardiovascular drugs and devices by the U.S. Food and Drug Administration (FDA). Purpose: To catalogue the health status patient-reported outcome measures (PROMs) validated in cardiovascular diseases (CVDs), describe their psychometric properties, and assess adherence…
Source: Annals of Internal MedicineCategories: Cardiologists, Latest HeadlinesTweet-
@iamritu @JACCJournals @ShahzebKhanMD @krychtiukmd @mmamas1973 @SJGreene_md @AndrewJSauer @KBreathettMD @BiykemB @GiuseppeGalati_ @DrAsifQasim @SantosGallegoMD Agree, validated #HealthStatus #diseasespecific #PROs are more sensitive to changes in health status than clinician-centric scales such as #NYHA. #PROs used to assess value / health utilities are not as sensitive or adequately validated in #HF. https://t.co/qbE1MKXIfE
-
-
Mashup Score: 6Source: link.springer.comCategories: Latest Headlines, Oncologists2Tweet
-
https://t.co/NcxZSVbEbE https://t.co/k3bM7Q0agY
-
Our paper on #implementation of #PROs in #cancer: symptoms and needs common BUT uptake by nurses (and patients) lower than expected. 🤔@Lisa_Beatty @KnowlesReegan @Joanne472 @hagsie @TriggerShep @jonkarnon https://t.co/NcxZSVbEbE https://t.co/FXZpIuFCrR
-
-
Mashup Score: 0PIK3CA-Related Overgrowth Syndrome (PROS) Explained - 1 year(s) ago
Guillaume Canaud, MD, PhD, of the Paris Descartes University, provides an overview of PIK3CA-related overgrowth syndromes (PROS).
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Guillaume Canaud, MD, PhD, of Necker-Enfants Malades Hospital – AP-HP, the Paris Descartes University, provides an overview of PIK3CA-related overgrowth syndromes, a group of rare disorders caused by PIK3CA gene mutation. #PROS https://t.co/KRNliSBxwM
-
-
Mashup Score: 0Is Surgery a Good Option for Patients With PIK3CA-Related Overgrowth Syndrome (PROS)? - 1 year(s) ago
Dr Guillaume Canaud explains why surgery is usually not an effective treatment in the long-term for patients with PROS.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Guillaume Canaud, MD, PhD, of Necker-Enfants Malades Hospital – AP-HP, the Paris Descartes University, explains why surgical intervention to treat PIK3CA-related overgrowth syndromes #PROS is not always the best option. @PROS_PIK3CA @upemlv https://t.co/BtgAixGvdq
-
-
Mashup Score: 0
Abstract. Randomized clinical trials are critical for evaluating the safety and efficacy of interventions in oncology and informing regulatory decisions, practi
Source: OUP AcademicCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
This @JNCI_Now commentary analyzes nine #clinicaltrials to show how #patientreportedoutcomes (PROs) add value using two frameworks on how #PROs are used in clinical trials and how #PROs have an impact while representing the #patientvoice. Read more here: https://t.co/YlpEkY7CyJ https://t.co/8HrtshRHkL
-
-
Mashup Score: 0
Dr. Guillaume Canaud explains why regularly measuring objective outcomes in persons with PiK3CA-related overgrowth syndromes (PROS) is important.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Guillaume Canaud, MD, PhD, of the Paris Descartes University, explains why it is important to regularly measure objective outcomes in persons with PiK3CA-related overgrowth syndrome #PROS @upemlv @PROS_PIK3CA https://t.co/EpfkE95bYJ
-
-
Mashup Score: 0PIK3CA-Related Overgrowth Syndrome (PROS) Explained - 1 year(s) ago
Guillaume Canaud, MD, PhD, of the Paris Descartes University, provides an overview of PIK3CA-related overgrowth syndromes (PROS).
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Guillaume Canaud, MD, PhD, of Necker-Enfants Malades Hospital – AP-HP, the Paris Descartes University, provides an overview of PIK3CA-related overgrowth syndromes, a group of rare disorders caused by PIK3CA gene mutation. #PROS https://t.co/KRNliSBxwM
-
-
Mashup Score: 0Is Surgery a Good Option for Patients With PIK3CA-Related Overgrowth Syndrome (PROS)? - 1 year(s) ago
Dr Guillaume Canaud explains why surgery is usually not an effective treatment in the long-term for patients with PROS.
Source: CheckRareCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Guillaume Canaud, MD, PhD, of Necker-Enfants Malades Hospital – AP-HP, the Paris Descartes University, explains why surgical intervention to treat PIK3CA-related overgrowth syndromes #PROS is not always the best option. @PROS_PIK3CA @upemlv https://t.co/BtgAixGvdq
-
Guillaume Canaud, MD, PhD, of Necker-Enfants Malades Hospital – AP-HP, the Paris Descartes University, explains why surgical intervention to treat PIK3CA-related overgrowth syndromes #PROS is not always the best option. @PROS_PIK3CA @upemlv https://t.co/BtgAixGvdq